The Latest Breaking News from Momentum

Amid the market uncertainty surrounded by high inflation, aggressive interest rate hikes, and economic slowdown, the meme stock frenzy has returned this year. However, considering the macroeconomic and geopolitical headwinds, it could be wise to avoid fundamentally weak meme stocks AMC Entertainment (AMC), Peloton Interactive (PTON), and Bed Bath &…

The fourth generation of the Momentum over-ear headphones has an impressive battery life, but a rather lazy redesign.

Raymond James Financial (RJF) has gained more than 7.5% over the past month, but it still appears to be under the radar of many investors considering its fundamental strength. Let’s discuss why the bank is well-positioned to maintain its momentum….

Labour leader puts focus on ‘growth, growth, growth’ but appears to step back from public ownership policy

The macroeconomic headwinds are leading to volatility in the energy market. However, efforts made to improve supply should benefit prominent energy stocks TETRA (TTI) and NOW (DNOW). But which of these stocks is a better buy now? Read more to find out….

The stock market has been under immense pressure owing to the growing concerns over a potential recession due to the tightening of monetary policy. Hence, we think it could be worth adding the Dow’s highest dividend-paying stocks, Goldman Sachs (GS), Merck (MRK), Coca-Cola Company (KO), Home Depot (HD), and McDonald's…

Increased health awareness and the rapidly aging population are expected to drive the growth of healthcare companies. Healthcare stocks Cigna Corp. (CI), Humana (HUM), and McKesson Corp. (MCK) have bucked the market downtrend and are in momentum. Since the market is expected to remain under pressure in the near term,…

Plus: A new lawsuit challenges D.C.'s ban on carrying guns on public transit, Denver's latest housing affordability initiative will make the city more expensive, and more...

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.